当前位置： SCI文献检索 > BMC GASTROENTEROLOGY期刊下所有文献 > Histological improvement in chronic hepatitis B patients treated with bicyclol: real world experience.

Histological improvement in chronic hepatitis B patients treated with bicyclol: real world experience.

Abstract：

BACKGROUND:Bicyclol, the most commonly-used liver hepatoprotective drug in China, is often selected to control disease progression in CHB patients who refuse anti-viral treatment. However, data on histological changes after bicyclol treatment in these patients are scarce. Therefore, this study has been conducted to find out whether bicyclol has good benefits of histological improvement in CHB patients who refuse anti-viral agents. METHODS:The demographic, clinical and pathological data were collected from CHB patients who received bicyclol from January 2010 to June 2016. Improvement in liver inflammation or fibrosis is defined as at least one-grade or one-stage decrease as measured by the Scheuer scoring system. Thirty patients treated with ETV for 48 weeks were chosen as a control group to compare the histological improvement between bicyclol and entecavir (ETV) after 48-week treatment. RESULTS:A total of 123 patients with CHB treated with bicyclol were included in this study. Paired liver biopsies were performed in 70 patients. Inter-biopsy interval was 17.44 ± 8.90 months (12-60 months). As shown by facts, 41.4% patients achieved liver inflammation improvement, while only 10.0% patients showed liver inflammation progression after bicyclol treatment. In regarding to liver fibrosis, as shown by facts, 28.6% patients achieved fibrosis improvement. More importantly, It was found that the proportions of patients with liver inflammation and fibrosis improvement were both not significantly lower than those in ETV group (53.3% vs 63.3 and 36.7% vs 43.4%). Most of patients (82.4%) with elevated baseline ALT became normal after bicyclol treatment. More importantly, as shown by the multi-variate analysis, the treatment course of bicyclol was an independent factor for liver inflammation improvement. With the HBeAg status adjusted, ALT and HBV-DNA quantity, the odds ratio (95% confidence interval) of patients with ≥48-week treatment was 5.756 (1.893,17.500) when compared with patients via < 48-week treatment. CONCLUSION:Bicyclol can improve liver inflammation and the ALT normalization rate of CHB patients, especially when the treatment course is prolonged. This has confirmed that bicyclol could control hepatitis activity, which might be a good choice for CHB patients who refuse anti-viral treatments.

journal_name

BMC Gastroenterol

journal_title

BMC gastroenterology

authors

Chi X,Xiao H,Shi M,Cai G,Xie Y,Jiang J,Tian G,Wu S,Zhang C,Zhao P,Chen J

doi

10.1186/s12876-019-1005-1

subject

Has Abstract

pub_date

2019-06-13 00:00:00

pages

issue

issn

1471-230X

pii

10.1186/s12876-019-1005-1

journal_volume

pub_type

杂志文章

在线工具

Histological improvement in chronic hepatitis B patients treated with bicyclol: real world experience.